Hims(HIMS) ZACKS·2025-05-02 16:00Core Viewpoint - Hims & Hers Health, Inc. is expected to report strong revenue and earnings growth for the first quarter of 2025, driven by increased subscriber numbers and expanded product offerings [4][5][15]. Group 1: Performance Metrics - The company ended Q4 2024 with nearly 2.2 million subscribers, a 45% year-over-year increase [2]. - Monthly online revenue per average subscriber rose by 37.7% year-over-year in Q4 2024, attributed to the scaling of GLP-1s and a shift to premium offerings [2]. - Hims & Hers generated 2.8 million net orders in Q4 2024, marking a 22.1% year-over-year increase [2]. - Average order value increased by 63.1% year-over-year in Q4 2024 [2]. Group 2: Revenue and Earnings Estimates - The Zacks Consensus Estimate for Q1 2025 revenues is $538.1 million, reflecting a 93.4% increase from the prior year [4]. - The consensus estimate for EPS is 12 cents, indicating a 140% surge from the previous year's figure [4]. Group 3: Strategic Developments - The company has expanded its brand to include a wider range of health specialties, which is expected to enhance revenue potential [3]. - A long-term collaboration with Novo Nordisk aims to improve accessibility to obesity treatments, potentially boosting revenues [15]. - Recent acquisitions, including a peptide facility and an at-home lab testing facility, are expected to strengthen the company's supply chain and service offerings [16]. Group 4: Valuation and Market Position - Hims & Hers has a forward 12-month price-to-sales (P/S) ratio of 3.2X, which is below the industry average of 5.3X [10]. - The company is trading at a discount compared to peers like Veeva Systems and Inspire Medical, suggesting potential for growth [11]. Group 5: Stock Performance - Over the past three months, Hims & Hers shares have decreased by 7.1%, outperforming the declines of its sector and the S&P 500 [7]. - Compared to peers, Hims & Hers has shown relative resilience, with some competitors experiencing larger declines [9].